Marburg Virus Disease Outbreaks in United Republic of Tanzania and Equatorial Guinea

Actions requested

• Be aware of two concurrent confirmed outbreaks of Marburg virus disease (MVD) — one in the United Republic of Tanzania (Tanzania) and Equatorial Guinea. No confirmed cases of MVD related to these outbreaks have been reported in other countries outside Equatorial Guinea and Tanzania and the current risk of MVD in the United States is low.
• Consider MVD in patients with compatible symptoms and history of concerning exposure while in an MVD affected area.
  • Illness typically onsets suddenly and progresses from “dry” symptoms (fever, aches, fatigue) to “wet” symptoms (diarrhea, vomiting, and in some cases, bleeding).
    
  • Symptoms include some or several of the following:
    
    • Fever >100.4° F,
      
    • Severe headache and muscle and/or joint pain,
      
    • Weakness and fatigue,
      
    • Sore throat,
      
    • Inappetence,
      
    • Gastrointestinal symptoms including abdominal pain, diarrhea, and vomiting,
      
    • Unexplained hemorrhaging, bleeding or bruising,
      
    • Red eyes, rash (maculopapular, most prominent on the trunk), and hiccups.
      
  • Incubation period is 2–21 days following exposure.
    
  • Alternative diagnoses such as malaria, influenza, COVID-19 or other common causes of febrile and gastrointestinal illness in persons with recent international travel should be considered, evaluated, and managed appropriately.
    
  • Transmission occurs through contact (through broken skin or mucous membranes) with the blood or other body fluids (including urine, saliva, sweat, feces, vomit, breast milk, amniotic fluid, or semen) of a person who is sick with or has died from MVD, with the body fluids of infected animals, or with needles or other fomites that are contaminated with the virus; Marburg virus is not spread through airborne transmission.
• Inquire about travel history and exposure risk in patients with compatible symptoms:
  • Having contact with a symptomatic person with suspected or confirmed MVD, or any objects contaminated by their body fluids;
    
  • Experiencing a breach in infection prevention and control precautions that result in the potential for contact with body fluids of a patient with suspected or confirmed MVD;
    
  • Having contact with semen from a man who has recovered from MVD;
    
  • Participating in any of the following activities while in an area with an active MVD outbreak:
    • Contact with someone who was sick or died, or any objects contaminated by their body fluids;
      
    • Attend/participate in funeral rituals, including preparation of bodies for funeral/burial;
      
    • Work in a healthcare facility or laboratory;
      
    • Visit a healthcare facility or traditional healer;
      
    • Contact with bats or wild animals;
      
    • Work or spend time in a mine/cave.
• Consider treatment with supportive care measures in suspected cases; there is no specific treatment for MVD and no vaccination.
  • In the absence of early diagnosis and supportive care, MVD has high mortality rates of between 23%-90%.
• Inform infection prevention and control promptly if a patient is suspected of MVD or other viral hemorrhagic fever and implement appropriate infection prevention measures.
  • Infection prevention measures for MVD are the same as for Ebola Virus Disease, and include the following:
    • Isolate the patient in a single-occupancy room with the door closed and log all staff and visitors entering the room until receiving a negative Marburg virus test on a sample collected >72 hours after symptom onset.
      
    • Ensure all staff wear appropriate PPE and dispose of PPE appropriately. Separate PPE guidance is available for management of clinically stable and unstable patients.
      
    • Limit aerosol-generating procedures.
• Counsel patients with planned travel to outbreak-affected areas on ways to prevent exposure to MVD.
• Immediately notify Public Health at 206- 296-4774 if Marburg virus disease is suspected.
  • Testing may be coordinated by Public Health for patients with compatible risk factors and symptoms following consultation with CDC and Public Health.